

CORPORATE NEWS

MeVis Medical Solutions AG
Caroline-Herschel-Straße 1
28359 Bremen
Germany

Phone: +49 421 224 95 0
Fax: +49 421 224 95 999
E-mail: ir@mevis.de

Path cleared for Varian acquisition of majority stake of MeVis

VMS Deutschland Holdings GmbH waives Minimum Acceptance Threshold

- Acceptance Period extended to March 24th
- Transition of majority stake to Varian expected by mid-April
- Executive Board and Supervisory Board publish supplementary joint statement on the amendment of the takeover offer

Bremen, March 12, 2015 – Executive Board and Supervisory Board of MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading provider of medical imaging software, today published a supplementary joint reasoned statement pursuant to § 27 Section 1 of the German Securities Acquisition and Takeover Act (WpÜG) on the amendment of the voluntary public takeover offer (cash offer) of VMS Deutschland Holdings GmbH published on March 9, 2015.

VMS Deutschland Holdings GmbH, based in Darmstadt, an affiliate of Varian Medical Systems, Inc., Palo Alto, California, USA, published a voluntary public takeover offer on January 27, 2015 to all shareholders of MeVis Medical Solutions AG to acquire their registered non-par value shares against payment of 17.50 Euros per share. The offer was subject to the condition of a Minimum Acceptance Threshold of 75 % of the shares issued by MeVis Medical Solutions AG (excluding treasury shares).

On March 9, 2015 VMS Deutschland Holdings GmbH has published an amendment of the takeover offer, waiving the Minimum Acceptance Threshold of 75 %. Thus the offer is no longer subject to any conditions. The VMS Deutschland Holdings GmbH is expected to acquire the majority stake by mid-April 2015. Through the amendment of the takeover offer the Acceptance Period is extended by two weeks to March 24, 2015, 12 pm.

The publication of the offer document and the amendment of the offer by VMS Deutschland Holdings GmbH as well as further information, relevant to the tender offer, are made available in the internet at <http://www.variango1.de>.

Executive Board and Supervisory Board still welcome the offer and continue to see Varian Medical Systems as a reliable partner for the further development of MeVis Medical Solutions AG. They therefore also welcome the amendment of the offer, as it increases the probability of a successful execution of the offer.

“We are very pleased that there is now substantial certainty with regard to the transaction, because Varian waived the Minimum Acceptance Threshold.” said Marcus Kirchhoff, CEO of MeVis Medical Solutions AG. Dr. Robert Hannemann, CFO of MeVis Medical Solutions AG, added: “Since January 2014 our risk increased because of our strong dependency on our largest customer Hologic. Now we assume that this risk will be significantly mitigated by our future affiliation to a large market participant such as Varian.”

The complete text of the supplementary joint reasoned statement is published in the Internet at www.mevis.de under Investor Relations/ Aktie/ Übernahmeangebot in German language and is held available free of charge at MeVis Medical Solutions AG, Investor Relations, Caroline Herschel-Strasse 1, 28359 Bremen, Tel: +49 (0) 421-22495 0 Fax: +49 (0) 421-22495 499 , E-mail: ir@mevis.de.

MeVis Medical Solutions AG was founded in 1997 and is one of the world's leading independent developer and provider of medical imaging software with focus on dedicated, disease-oriented clinical applications. MeVis AG has been listed on the Frankfurt Stock Exchange in the Prime Standard segment of the Regulated Market since November 16, 2007.

Over the past few years, there has been an enormous increase in the complexity and volume of medical imaging data derived from diagnostic imaging processes such as digital mammography, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US). MeVis' products analyze and process this data in such a way as to provide medical professionals with crucial information for early detection, diagnosis and intervention in the areas of cancer and lung diseases as well as neurological disorders. The Company develops its software solutions in close consultation with world's leading medical experts and original equipment manufacturers (OEM) in the medical technology sector and primarily markets this software via these partnerships.